ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

BRMP Projects Priority Rated

April 11, 1980

Pazdur Waxes On Calumet City And Krebiozen; Parkinson Takes Interim CMO Job at Zyngenia

April 27, 2012

Funding Opportunities: NCI’s RAPID Program; RFA, Pas Avilable

May 14, 1999

UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer

June 26, 2013

DCT Board Approves Contract Recompetitions Worth 44.8 Million In First Year Awards

November 5, 1982